Congress Reports

16-18 November, Chicago, USA

American Heart Association Scientific Sessions 2024

Muvalaplin significantly reduces Lp(a) in KRAKEN trial

ALPACAR trial shows zerlasiran reduces Lp(a) and LDL-C

30 August-2 September, London, UK

ESC 2024 Highlights

Lp(a) as a treatment target in aortic stenosis

Lp(a) level aids 30-year CV risk prediction

30 May-2 June, Las Vegas, USA

Overview of NLA 2024

Lp(a) and premature ASCVD family history

Attitudes and barriers to Lp(a) testing

26-29 May, Lyon, France

Overview of EAS 2024

High Lp(a) causally linked to chronic kidney disease

Elevated Lp(a) enhances CV risk estimates in patients with HeFH

6-8 April, Atlanta, USA

Overview of ACC.24 News

Real world data support link between Lp(a) and CV events

Impact of Lp(a) testing on lipid management

11-13 November, Philadelphia, USA

Overview of AHA 2023 News

Small apoA isoforms linked to worse PAD revascularisation outcomes

OCEAN(a)-DOSE study highlights Lp(a) variability with time

Educational Partners and Supporters